Sanofi (NASDAQ:SNY) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET

Company Participants

Thomas Kudsk - Head of Investor Relations
Paul Hudson - Chief Executive Officer
Francois Roger - Executive Vice President, Chief Financial Officer
Houman Ashrafian - Executive Vice President, Head of Research and Development
Thomas Triomphe - Executive Vice President, Vaccines
Brian Foard - Executive Vice President, Head of Specialty Care
Brendan O'Callaghan - Executive Vice President, Manufacturing and Supply
Roy Papatheodorou - Executive Vice President, General Counsel

Conference Call Participants

Richard Vosser - JPMorgan
Emily Field - Barclays
Graham Parry - BofA
Seamus Fernandez - Guggenheim
Jo Walton - UBS
Peter Welford - Jefferies
Luisa Hector - Berenberg
Thibault Boutherin - Morgan Stanley
Simon Baker - Redburn
Steve Scala - TD Cowen
David Risinger - Leerink
Richard Parkes - BNP Exane
Rajesh Kumar - HSBC
Eric Berrigaud - Stifel
Florent Cespedes - Bernstein

Thomas Kudsk

Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com. Please turn to slide number three.

Here we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which is subject to substantial risks and uncertainties that may cause actual results to differ materially.

We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our Form 20-F on file with the US SEC on d'Enregistrement document for a description of these risk factors.

As usual, we'll be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in million euros and for Q3 2024 unless stated otherwise.

Please turn to slide number four. First, we have a presentation then we'll take your questions. As last time, we kept the presentation on the shorter side to allow for more questions, and we aim at keeping the call to about one hour.

For Q&A, we have Brian, Olivier, Thomas and Julie to cover the global business and Roy, our General Counsel.

For the Q&A, you have two options in Zoom, raise your hand or submit your questions using the Q&A function.

And with this I'll now hand you over to Paul.

Paul Hudson

Thank you, Thomas. Nicely done. Thank you, and hello, everyone, on the call. We reaffirmed strong sales performance this year. The total of Q3 sales of EUR13.4 billion, a 16% increase in CER and estimated 11% excluding the impact of phasing.